# A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

> **NCT03716570** · PHASE1 · TERMINATED · sponsor: **Biogen** · enrollment: 24 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** BIIB054
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03716570
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-12
- **Primary completion:** 2021-04-23
- **Final completion:** 2021-04-23
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Affiliated study NCT03318523 did not meet its primary outcome measure of change from baseline measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and did not demonstrate efficacy on secondary outcome measures
- **Last updated:** 2021-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03716570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03716570, "A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03716570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*